ALSPW.PA Spineway

Healthcare Health Care Equipment & Supplies Euronext Paris
0.0950 EUR
Close of Nov 8, 2026
0.0816 0.2110
Market cap
EUR 3.38M
P/E
-
P/B
0.15x
ROE
-
Dividend yield
-
Fundamental score
1.8/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALSPW.PA undervalued?

Graham number

The Graham number of Spineway cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Spineway fundamental analysis

4 of 11 checks passed

ROE 0/2

The stock's ROE indicates a negative return (-4.15%) on shareholders' equity, suggesting poor financial performance.

ROA 0/2

The stock's ROA (-2.75%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

PBV 2/2

The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.

DER 2/2

The stock has a minimal amount of debt (10%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

Revenue Growth 0/2

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

Net Profit Growth 0/2

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

Assets Growth 2/2

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

Graham Number 1/1

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

Dividend Growth 0/2

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Dividend 0/2

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

Buffet Intrinsic Value 0/1

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Spineway stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Spineway

Spineway SA designs, develops, and markets a range of surgical implants for spine in France. The company offers posterior fixation, including posterior osteosynthesis systems and minimal invasive posterior osteosynthesis systems; interbody fusion products, such as lumbar cage twin peaks tlif curved and oblique; motion preservation products; and biomaterials. It also exports its products. The company was incorporated in 2005 and is headquartered in Ecully, France.

Full company profile